Abstract
Substance P receptor (SPR), a G protein-coupled receptor (GPCR), is found in human glioblastomas, and has been implicated in their growth. Consistent with a role for SPR in cell growth, activation of SPR in U373 MG human glioblastoma cells leads to the phosphorylation of mitogen-activated protein kinases [extracellular signal-regulated kinase 1 and 2 (ERK1/2)] and stimulation of cell proliferation. The purpose of the present study was to elucidate the pathway through which these actions occur. Using either the epidermal growth factor receptor (EGFR) kinase inhibitor, AG 1478, or a small-interfering RNA (siRNA) directed against human EGFR, we found that transactivation of EGFR by SPR is only marginally involved in SP-dependent ERK1/2 phosphorylation. Src, however, is shown to be a major component of SPR signaling because the Src kinase inhibitor, PP2, and a kinase-dead Src mutant both inhibit SP-dependent ERK1/2 phosphorylation. We also report that SPR stimulates the phosphorylation of protein kinase Cδ(PKCδ), and that this stimulation is blocked by PP2. SP-dependent ERK1/2 phosphorylation is also blocked by rottlerin, a PKCδ inhibitor, and the calcium scavenger, BAPTA/AM. Finally, rottlerin and PP2 were both found to inhibit the growth of several glioblastoma cell lines, underscoring the potential of these agents to block glioblastoma growth.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00280-005-1030-3/MediaObjects/s00280-005-1030-3fhb1.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00280-005-1030-3/MediaObjects/s00280-005-1030-3fhb2.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00280-005-1030-3/MediaObjects/s00280-005-1030-3fhb3.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00280-005-1030-3/MediaObjects/s00280-005-1030-3fhb4.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00280-005-1030-3/MediaObjects/s00280-005-1030-3fhb5.jpg)
Similar content being viewed by others
Abbreviations
- SPR:
-
Substance P receptor
- GPCR:
-
G protein-coupled receptor
- SP:
-
Substance P
- PKC:
-
Protein kinase C
- ERK1/2:
-
Extracellular signal-regulated kinase 1 and 2
- EGFR:
-
Epidermal growth factor receptor
- BAPTA/AM:
-
1,2-bis-(o-Aminophenoxy)ethane-N, N, N′, N′-tetraacetic acid tetra-(acetoxymethyl) ester
- PP2:
-
4-Amino-5-(4-chlorphenyl)-7-(tbutyl) pyrazolo[3,4-d]pyrimidine
- PP3:
-
4-Amino-7-phenylpyrazol[3,4-d]pyrimidine
- EGF:
-
Epidermal growth factor
- PMA:
-
Phorbol-12-myristate-13-acetate
- GF109203X:
-
Bisindoylmaleimide I
References
Otsuka M, Yoshioka K (1993) Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73:229–308
Palma C, Maggi CA (2000) The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci 67:985–1001
Hennig IM, Laissue JA, Horisberger U, Reubi JC (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61:786–792
Luo W, Sharif TR, Sharif M (1996) Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 56: 4983–4991
Palma C, Nardelli F, Manzini S, Maggi CA (1999) Substance P activates responses correlated with tumour growth in human glioma lines bearing tachykinin NK1 receptors. Br J Pharmacol 79:236–243
Palma C, Goso C, Manzini S (1994) Different susceptibility to neurokinin 1 receptor antagonists of substance P and septide-induced interleukin-6 release from U373 MG human astrocytoma cell line. Neurosci Lett 171:221–224
Gillespie GY (1996) Cytokines as modulators of malignant glioma progression. In: Ransohoff RM, Beneviste EM (eds) Cytokines and the CNS.CRC Press, Boca Raton, pp 269–286
Johnson CL, Johnson CG (1992) Characterization of receptors for substance P in human astrocytoma cells: radioligand binding and inositol phosphate formation. J Neurochem 58:471–477
Luo W, Sharif TR, Houghton PJ, Sharif M (1997) CGP 4125 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells. Cell Growth Diff 8:1225–1240
Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K (2000) The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-κB. J Immunol 165:5606–5611
Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K (1997) The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 159:4952–4958
Castagliuolo I, Valenick L, Liu J, Pothoulakis C (2000) Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells. J Biol Chem 275:26545–26550
Miller WE, Maudsley S, Ahn S, Khan KD, Luttrell LM, Lefkowitz RJ (2000) β-Arrestin1 interacts with the catalytic domain of the tyrosine kinase c-SRC. J Biol Chem 275:11312–11319
Roush ED, Warabi K, Kwatra MM (1999) Characterization of differences between rapid agonist-dependent phosphorylation and phorbol ester-mediated phosphorylation of human substance P receptor in intact cells. Mol Pharmacol 55:855–862
Roush ED, Kwatra MM (1998) Human substance P receptor expressed in Chinese hamster ovary cells directly activates Gαq/11, Gαs, and Gαo. FEBS Lett 428:291–294
Pierce KL, Luttrell LM, Lefkowitz RJ (2001) New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20:1532–1539
DeFea KA, Vaughn ZD, O’Bryan EM, Nishijima D, Déry O, Bunnett NW (2000) The antiproliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 97:11086–11091
Traxler P, Bold G, Frei J, Lang N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P (1997) Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 40:3601–3616
Benes C, Soltoff SP (2001) Modulation of PKCδ tyrosine phosphorylation and activity in salivary and PC-12 cells by Src kinases. Am J Physiol Cell Physiol 280:C1498–C1510
Tapia JA, García-Marin LJ, Jensen RT (2003) Cholecystokinin-stimulated protein kinase C-δ kinase activation, tyrosine phosphorylation, and translocation are mediated by Src tyrosine kinases in pancreatic acinar cells. J Biol Chem 278:35220–35230
Robin P, Boulven I, Bole-Feysot C, Tanfin Z, Leiber D (2004) Contribution of PKC-dependent and -independent processes in temporal ERK regulation by ET-1, PDGF, and EGF in rat myometrial cells. Am J Physiol Cell Physiol 286:C798–C806
Greco S, Muscella A, Elia MG, Romano S, Storelli C, Marsigliante S (2004) Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. J Cell Physiol 201:84–96
Treiman M, Caspersen C, Christensen SB (1998) A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca2+-ATPases. Trends Pharmacol Sci 19:131–135
Parmer TG, Ward MD, Hait WN (1997) Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Cell Growth Diff 8:327–334
Biscardi JS, Tice DA, Parsons SJ (1999) c-Src, receptor tyrosine kinases and human cancer. Adv Cancer Res 76:61–119
Staley CA, Parikh NU, Gallick GE (1997) Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Diff 8:269–274
Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21:187–190
Susa M, Missbach M, Green J (2000) Src inhibitors: drugs for the treatment of osteoporosis, cancer or both. Trends Pharmacol Sci 21: 489–495
Yeatman TJ (2004) A renaissance for Src. Nat Rev Cancer 4: 470–480
Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA (1986) Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 261:13754–13759
Hussaini IM, Karns LR, Vinton G, Carpenter JE, Redpath GT, Sando JJ, VandenBerg SR (2000) Phorbol 12-myristate 13-acetate induces protein kinase Cη - specific proliferative response in astrocytic tumor cells. J Biol Chem 275:22348–22354
Mandil R, Ashkenazi E, Blass M, Kronfeld I, Kazimirsky G, Rosenthal G, Umansky F, Lorenzo PS, Blumberg PM, Brodie C (2001) Protein kinase Cα and protein kinase Cδ play opposite roles in proliferation and apoptosis of glioma cells. Cancer Res 61:4612–4619
Zrachia A, Dobroslav M, Blass M, Kazimirsky G, Kronfeld I, Blumberg PM, Kobiler D, Lustig S, Brodie C (2002) Infection of glioma cells with sindbis virus induces selective activation and tyrosine phosphorylation of protein kinase Cδ. J Biol Chem 277:23693–23701
Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK, Parmer S, Giafis N, Kalvakolanu DV, Rahman A, Uddin S, Minucci S, Tallman MS, Fish EN, Platanias LC (2003) Activation of protein kinase Cδ by all-trans-retinoic acid. J Biol Chem 278:32544–32551
Li W, Jiang Y-X, Zhang J, Soon L, Flechner L, Kapoor V, Pierce JH, Wang L-H (1998) Protein kinase C-δ is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation. Mol Cell Biol 18:5888–5898
Jackson DN, Foster DA (2004) The enigmatic protein kinase Cδ: complex roles in cell proliferation and survival. FASEB J 18:627–636
Ginnan R, Pfleiderer PJ, Pumiglia K, Singer HA (2004) PKC- and CaMKII-δ2 mediate ATP-dependent activation of ERK1/2 in vascular smooth muscle. Am J Physiol Cell Physiol 286:C1281–C1289
Gschwendt M, Müller H-J, Kielbassa K, Zang R, Kittstein W, Rincke G, Marks F (1994) Rottlerin, a novel protein kinase inhibitor. Bioch Biochem Biophys Res Commun 199:93–98
Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK, Huang HJ (2001) Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95: 472–479
Efferth T, Ramirez T, Gebhart E, Halatsch ME (2004) Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol 67:1689–1700
Acknowledgements
This work was supported in part by National Institutes of Health Grant NS 33405 (to M.M.K.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamaguchi, K., Richardson, M.D., Bigner, D.D. et al. Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCδ. Cancer Chemother Pharmacol 56, 585–593 (2005). https://doi.org/10.1007/s00280-005-1030-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-005-1030-3